Table 2.
Primary analysis outcomes calculated with multivariable analysis using caliper distance of 0·5 SDs for propensity score
| Bedaquiline group (events/total) | Injectable group (events/total) | Matched pairs (% of patients matched) | Adjusted risk difference, % (95% CI) | |
|---|---|---|---|---|
| Total population | ||||
| Success versus all other outcomes | 478/688 | 396/699 | 485 (70%) | 14% (8 to 20) |
| Survival versus death | 526/688 | 500/699 | 485 (70%) | 8% (3 to 14) |
| Disease-free survival versus survival with treatment failure or recurrence | 522/526 | 483/500 | 338 (66%) | 2% (0 to 5) |
| Loss to follow-up versus all other outcomes | 478/688 | 396/699 | 485 (70%) | −4% (−8 to −1) |
| PLHIV receiving antiretroviral therapy | ||||
| Success versus all other outcomes | 337/478 | 245/440 | 345 (75%) | 14% (7 to 22) |
| Survival versus death | 372/478 | 302/440 | 345 (75%) | 10% (3 to 16) |
| Disease-free survival versus survival with treatment failure or recurrence | 368/372 | 296/302 | 238 (71%) | 1% (−1 to 3) |
| Loss to follow-up versus all other outcomes | 31/478 | 51/440 | 345 (75%) | −5% (−9 to −1) |
| People HIV-Negative | ||||
| Success versus all other outcomes | 138/195 | 137/225 | 128 (61%) | 16% (4 to 27) |
| Survival versus death | 147/195 | 179/225 | 128 (61%) | 4% (−7 to 14) |
| Disease-free survival versus survival with treatment failure or recurrence | 147/147 | 169/179 | 93 (57%) | 4% (0 to 8) |
| Loss to follow-up versus all other outcomes | 9/195 | 32/225 | 128 (61%) | −8% (−15 to −1) |
| AFB smear-positive at baseline | ||||
| Success versus all other outcomes | 205/297 | 142/248 | 195 (72%) | 15% (5 to 24) |
| Survival versus death | 224/297 | 186/248 | 195 (72%) | 3% (−6 to 12) |
| Disease-free survival versus survival with treatment failure or recurrence | 223/224 | 177/186 | 135 (66%) | 5% (1 to 9) |
| Loss to follow-up versus all other outcomes | 18/297 | 35/248 | 195 (72%) | −9% (−15 to −3) |
| AFB smear-negative at baseline | ||||
| Success versus all other outcomes | 224/307 | 189/322 | 209 (66%) | 17% (8 to 26) |
| Survival versus death | 244/307 | 230/322 | 209 (66%) | 13% (5 to 22) |
| Disease-free survival versus survival with treatment failure or recurrence | 242/244 | 223/230 | 143 (60%) | −1% (−3 to 2) |
| Loss to follow-up versus all other outcomes | 18/307 | 34/322 | 209 (66%) | −4% (−9 to 0) |
| Previously treated with first-line drugs | ||||
| Success versus all other outcomes | 181/274 | 153/286 | 186 (66%) | 14% (4 to 24) |
| Survival versus death | 198/274 | 188/286 | 186 (66%) | 10% (0 to 19) |
| Disease-free survival versus survival with treatment failure or recurrence | 196/198 | 181/188 | 124 (64%) | 2% (−2 to 7) |
| Lost to Follow-up vs. All Other Outcomes | 15/274 | 28/286 | 186 (66%) | −3% (−8 to 3) |
| Never previously treated for tuberculosis | ||||
| Success versus all other outcomes | 297/414 | 243/413 | 295 (71%) | 12% (4 to 19) |
| Survival versus death | 328/414 | 312/413 | 295 (71%) | 6% (−1 to 13) |
| Disease-free survival versus survival with treatment failure or recurrence | 326/328 | 302/312 | 211 (66%) | 2% (−0 to 5) |
| Loss to follow-up versus all other outcomes | 29/414 | 59/413 | 295 (71%) | −4% (−9 to 0) |
All estimates were derived from a model in which patients were matched exactly on HIV, ART, previous treatment, and baseline smear and culture results, and propensity score matched on age, sex, province of treatment, and isoniazid resistance. AFB=acid fast bacilli. PLHIV=people living with HIV.